Nanna Therapeutics Ltd.
http://www.nannatherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nanna Therapeutics Ltd.
Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D
As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.
Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Nanna Acquisition Gives Astellas Mitochondrial Expertise
Japanese firm pays cash plus milestones for UK specialist as it looks to integrate novel screening platform and gain know-how in mitochondrial modulators with potential applications.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Astellas Pharma Inc.
- Bactevo Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice